Remove Dosage Remove FDA Remove Specialty Pharmacies
article thumbnail

Once Monthly Oral PrEP Medication Will Advance to Phase 3 Study

Drug Topics

Recent Videos Related Content FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1 Killian Meara July 10th 2025 Article The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. Subscribe Now!

article thumbnail

Eli Lilly Adds Highest Doses of Zepbound to Online Pharmacy Platform

Drug Topics

1 "Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. As part of the program, all dosages of semaglutide will be delivered directly to the patient’s home and filled by CenterWell Pharmacy. With the new addition, 12.5

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

TikTok Videos on IBD Provide Low Quality Information

Drug Topics

link] Recent Videos Related Content FDA Grants Expanded Interchangeability Designation to Yuflyma Ashley Gallagher May 23rd 2025 Article Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

FDA 281
article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

SHOW MORE The FDA approved acalabrutinib as a frontline option for untreated mantle cell lymphoma. Mann School of Pharmacy and Pharmaceutical Sciences. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. January 16, 2025.

FDA 56
article thumbnail

Self-Care Measures for Preventing and Managing Dysmenorrhea

Pharmacy Times

Selection of an appropriate OTC analgesic should take into consideration various patient factors, including the patient’s overall health status, current medical conditions, and medication profile, as well as patient preferences, which are often influenced by dosage form, required dosing intervals, and cost of OTC medication.

article thumbnail

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma

Pharmacy Times

It will be interesting to see what dosage form these data prompt the future development of. It also introduces a question on how to optimize the PK/pharmacodynamic profile for protein degraders, such as cereblon E3 ligase modulatory drugs and proteolysis-targeting chimeras, which are a burgeoning area of therapeutic development.”

article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

2 There are several FDA-approved adalimumab biosimilars—including interchangeable products—that are available to patients. 1 Specialty pharmacy dispensing data identified 67 patients with a diverse range of inflammatory conditions for study screening, and of this group, only 32 had eligibility criteria for enrollment.